NASDAQ
1.54USD
-0.07 (-4.35%)
We have scored 5 news catalysts on Silo Pharma, Inc. (SILO) over the past 12 months. The biggest single-day move next to one of them came Sep 30, 2026, when SILO closed −2.4%: “Silo Pharma's QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility”. Coverage across the window leans positive (average ticker sentiment +0.60). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8M
P/E
—
EPS
—
Beta
0.75
52W range
1.61-10.875
Day range
1.50–1.60
Open
1.60
Prev close
1.61
Volume
165.6K
Avg volume
149.7K
Dividend
0.00
IPO
2021-01-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Silo Pharma, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SILO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
